Nicholas Meyers

Biography

Dr Nick Meyers is an experienced Programme Director with over 20 years’ experience within the industry, working in large pharma, biotech and the CRO sector, delivering internally-resourced and out-sourced projects involving multi-disciplinary teams spanning different companies and geographies. Since moving into industry in the mid-1990s, Nick spent 8 years with SmithKline Beecham leading internal research projects and collaborations with academic groups, working and publishing in a number of diverse fields (e.g., oral microbiology, dermatology, hepatology), followed by 12 years working in two small, virtual biotech companies in the UK (Alizyme Therapeutics Ltd and Phytopharm plc), where he was responsible, respectively, for the development of novel small molecules for the treatment of IBS-C & IBS-A and Parkinson’s disease & ALS, taking those assets from pre-clinical development through late-stage clinical trials. Latterly, Nick has worked for the global CRO, PPD Ltd, providing programme management support for biotech and small pharma companies developing small molecule and biologics for the treatment of airway diseases; and most recently with Daiichi Sankyo Development, providing programme management expertise for two products being developed for the treatment of pain indications and a product being developed for the treatment of asthma. The breadth and depth of Nick’s R&D experience is considerable, spanning CMC, non-clinical, clinical and regulatory. Throughout his career Nick has worked in close collaboration with commercial colleagues and has previously been closely involved in licensing activities, establishing relationships with pharma partners and authoring patent applications/maintaining patent portfolios. Nick’s industry career was preceded by an academic career as a senior research fellow in virology within the Department of Pathology at the University of Cambridge and with the AFRC Institutes of Animal Health. Nick received his Ph.D in bacterial genetics in 1990, from the University of Cranfield.

Research Interest

onsiderable, spanning CMC, non-clinical, clinical and regulatory.